The global prevalence of diabetes continues to pose a significant health challenge, with millions affected by the chronic condition. Beyond managing blood sugar levels, the disease often brings complications such as insulin resistance and fatty liver disease, necessitating treatments that address these broader health risks.
Researchers are constantly exploring innovative solutions to enhance diabetes care, and one promising development is the discovery of a new compound, HPH-15.
Developed by researchers at Kumamoto University, HPH-15 offers a dual benefit by effectively regulating blood glucose levels while reducing fat accumulation.
This breakthrough combines glucose control with protective effects against complications linked to obesity, making it a potential game-changer in diabetes treatment.
The compound achieves these results through the activation of AMP-activated protein kinase (AMPK), a protein that plays a crucial role in maintaining energy balance in the body.
HPH-15 has shown superior efficacy compared to metformin, a widely used diabetes medication. Laboratory tests reveal that the compound activates AMPK and facilitates glucose uptake at concentrations 200 times lower than those required for metformin.
Additionally, it promotes the membrane translocation of GLUT4 proteins, which are essential for regulating blood sugar levels. These findings underline HPH-15’s potential as a more effective and efficient therapeutic option.
One of the standout advantages of HPH-15 is its ability to minimise side effects commonly associated with diabetes drugs. Metformin, for instance, can lead to lactic acidosis, a condition caused by high levels of lactic acid in the blood.
In comparison, HPH-15 produces equal or lower levels of lactic acid, significantly reducing the risk of this complication. This safer profile further enhances the compound’s appeal as a next-generation diabetes treatment.
Preclinical trials involving animal models have further validated the effectiveness of HPH-15. In studies conducted on mice fed a high-fat diet, the compound demonstrated remarkable results.
At a dose of 10 mg/kg, HPH-15 reduced blood glucose levels from 11.1 mmol/L to 8.2 mmol/L. At a higher dose of 100 mg/kg, glucose levels dropped even further to 7.9 mmol/L.
These reductions were comparable to those achieved by high doses of metformin, but with the added benefit of requiring much smaller quantities of HPH-15.
The compound’s benefits extend beyond glucose regulation. In the same preclinical trials, HPH-15 effectively suppressed fat accumulation and fibrosis in liver and adipose tissues.
Notably, mice treated with the compound experienced a 44% reduction in subcutaneous fat. This highlights its potential to address obesity-related complications, a significant concern for many individuals with diabetes.
Follow us
